arrow
T

Toni K. Choueiri

Dana-Farber Cancer Institute
H指数:149
被引数:12.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Summary of Research: Health-Related Quality-of-Life Profile and Clinical Outcomes in First-Line Advanced Renal Cell Carcinoma: A Modeling Analysis Based on the CheckMate 9ER Study

研究综述:与肾癌相关的生命质量特征和一线临床结果:基于CheckMate 9ER研究的模型分析

2026-10-080
OA
72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis

72 免疫检查点抑制剂输注的时间与肾细胞癌患者的总生存期:一项真实世界队列分析

2026-09-020
OAAI
11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

11 OMNIVORE试验的长期随访:适应性纳武利尤单抗和伊匹木单抗在晚期肾细胞癌中的疗效(NCT03652142)

2026-09-020
OAAI
54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

54 转移性肾细胞癌中一线纳武利尤单抗联合伊匹木单抗治疗的原发进展性疾病与结局:一项真实世界IMDC分析

2026-09-020
OAAI
49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma

49 合并症负担对belzutifan在转移性肾细胞癌患者中有效性和耐受性的影响

2026-09-020
OAAI
76 Defining Young-Onset Renal Cell Carcinoma (YORCC): a Registry-Based Analysis of Incidence Trends

定义年轻发病型肾细胞癌(YORCC):一项基于注册登记的研究发病率趋势分析

2026-09-020
OAAI
70 Lymphocyte Hsp70 is a Novel Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

70 淋巴细胞Hsp70是转移性肾细胞癌对免疫检查点抑制剂反应的新型预测生物标志物

2026-09-020
OAAI
75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

75 ARNT表达的相关转录特征及其对透明细胞肾细胞癌(ccRCC)生存结局的影响

2026-09-020
OAAI
51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

51 与肾细胞癌临床结局相关的耗竭CD8+ T细胞状态的发现

2026-09-020
OAAI
61 Differential Pattern of Disease Recurrence in Resected Renal Cell Carcinoma Patients Treated with Adjuvant Pembrolizumab Versus Observation: A Propensity Score-Weighted Analysis

61 接受辅助性帕博利珠单抗治疗与观察治疗的切除性肾细胞癌患者疾病复发的差异模式:一项倾向性评分加权分析

2026-09-020
OAAI
60 Germline Platelet Polygenic Risk Score Predicts Renal Cell Carcinoma Survival via Sustained Thrombocytosis

60 生殖系血小板多基因风险评分通过持续性血小板增多预测肾细胞癌生存

2026-09-020
OAAI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma

66 健康相关生活质量与疗效在LITESPARK-005研究(比较Belzutifan与Everolimus在先前治疗过的晚期透明细胞肾细胞癌中的效果)第三阶段的关系

2026-09-020
OAAI
88 PEAK-1 (NCT07011719): A Randomized, Double-Blind, Active-Control Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

PEAK-1 (NCT07011719):一项关于卡沙替法尼和卡博赞替尼与安慰剂和卡博赞替尼在晚期透明细胞肾细胞癌患者中进行的随机、双盲、活性对照III期试验

2026-09-020
OAAI
57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

57 TiNivo-2 III期试验的最终分析:替沃扎尼(Tivo)在转移性肾细胞癌(mRCC)患者中的长期结局

2026-09-020
OAAI
4 Baseline and Early On-Treatment Plasma Kidney Injury Molecule-1 (KIM-1) Levels are Associated with Outcomes in Advanced Renal Cell Carcinoma (aRCC)

基线和早期治疗期间血浆肾损伤分子-1(KIM-1)水平与晚期肾细胞癌(aRCC)患者的预后相关

2026-09-020
OAAI
85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

85 LITESPARK-033(NCT07227402)III期研究:比较贝舒替班联合赞赞林替尼与卡博赞替尼治疗接受辅助抗PD-(L)1治疗后复发透明细胞肾细胞癌的疗效

2026-09-020
OAAI
1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
74 HIF2α Downregulation and Clinical Outcomes in Patients with Clear Cell Renal Cell Carcinoma with and without Sarcomatoid Differentiation

74 HIF2α低表达及有无肉瘤样分化的透明细胞肾细胞癌患者的临床结局

2026-09-020
OAAI